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Abstract
Alpha-synuclein (ASYN) is a major constituent of the typical
protein aggregates observed in several neurodegenerative
diseases that are collectively referred to as synucleinopathies.
A causal involvement of ASYN in the initiation and progression
of neurological diseases is suggested by observations indi-
cating that single-point (e.g., A30P, A53T) or multiplication
mutations of the gene encoding for ASYN cause early onset
forms of Parkinson’s disease (PD). The relative regional
speciﬁcity of ASYN pathology is still a riddle that cannot be
simply explained by its expression pattern. Also, transgenic
over-expression of ASYN in mice does not recapitulate the
typical dopaminergic neuronal death observed in PD. Thus,
additional factors must contribute to ASYN-related toxicity. For
instance, synucleinopathies are usually associated with
inﬂammation and elevated levels of oxidative stress in affected
brain areas. In turn, these conditions favor oxidative modiﬁ-
cations of ASYN. Among these modiﬁcations, nitration of
tyrosine residues, formation of covalent ASYN dimers, as well
as methionine sulfoxidations are prominent examples that are
observed in post-mortem PD brain sections. Oxidative mod-
iﬁcations can affect ASYN aggregation, as well as its binding
to biological membranes. This would affect neurotransmitter
recycling, mitochondrial function and dynamics (ﬁssion/
fusion), ASYN’s degradation within a cell and, possibly, the
transfer of modiﬁed ASYN to adjacent cells. Here, we propose
a model on how covalent modiﬁcations of ASYN link energy
stress, altered proteostasis, and oxidative stress, three major
pathogenic processes involved in PD progression. Moreover,
we hypothesize that ASYN may act physiologically as a
catalytically regenerated scavenger of oxidants in healthy
cells, thus performing an important protective role prior to the
onset of disease or during aging.
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In a series of neurodegenerative disorders classiﬁed as
synucleinopathies, such as Parkinson’s disease (PD), PD
dementia with Lewy bodies, Lewy body variant of Alzhei-
mer’s disease, and multiple system atrophy, a common
feature is the formation and deposition of proteinaceous
aggregates, so-called Lewy bodies, and Lewy neurites
(Goedert et al. 2012; Lashuel et al. 2013). A major compo-
nent of these pathological aggregates is the 140 amino acid
pre-synaptic protein alpha-synuclein (ASYN) (Spillantini
et al. 1997, 1998). Besides the formation of Lewy inclusions,
another critical feature of PD is the degeneration of speciﬁc
neuronal populations, including dopaminergic (DA) neurons
of the substantia nigra (Hirsch et al. 1988). The relationship
between ASYN accumulation and neurodegeneration and the
molecular basis for the selectivity of this degeneration remain
relatively unclear. Several lines of evidence, however, justify
our current view that ASYN plays a major role in neurode-
generative processes both in idiopathic and familial PD
(McCormack et al. 2010). The observation of ASYN as a
major constituent of Lewy inclusions hints to its contribution
to the onset and progression of the idiopathic disease.
Perhaps, more direct evidence of a causal role of the protein
in neuronal injury comes from genetic studies. ASYN
mutations are a dominant trait for familial PD (Polymeropo-
ulos et al. 1996, 1997; Nussbaum and Polymeropoulos
1997). Indeed, point mutations in the ASYN gene, such as
the A53T, A30P, or the E46K mutations, were identiﬁed in
familial cases leading to early onset of parkinsonian symp-
toms (Polymeropoulos et al. 1996, 1997; Kr€uger et al. 1998;
Athanassiadou et al. 1999; Zarranz et al. 2004) including
motor impairment. Furthermore, duplications or triplications
of the gene encoding for ASYN were identiﬁed in familial
cases of PD that occurred with an early age of disease onset
(Singleton et al. 2003; Chartier-Harlin et al. 2004; Iba~nez
et al. 2004), suggesting that doubling the concentration of
ASYN is sufﬁcient to cause PD. Furthermore, genome wide
association studies indicated a link between the ASYN
(SNCA) locus and the risk of sporadic Parkinson’s disease
(Nalls et al. 2011).
Studies on the effects of modulating ASYN levels have
provided critical insight into the possible physiological
function(s) of the protein. Investigations made with animals
lacking ASYN revealed some subtle functional deﬁciencies
and suggested that ASYN can act as negative regulator of
DA neurotransmission and plays a role in modulating pre-
synaptic vesicle trafﬁcking and brain glucose metabolism
(Abeliovich et al. 2000; Murphy et al. 2000; Michell et al.
2007). Physiological regulation of the protein was ﬁrst
described in songbirds, as ASYN was enriched in pre-
synaptic terminals of deﬁned neuron populations during song
learning (George et al. 1995).
It is important to discriminate between observations of
ASYN knockdown, allowing to study physiological func-
tions of ASYN, and observations made with animals over-
expressing ASYN, which serve as models to study its
pathophysiological functions. Although ASYN-deﬁcient
mice exhibit normal development and only subtle functional
deﬁciencies, over-expression of ASYN in different trans-
genic models reproduces some, but not all aspects of PD
pathology (Buchman and Ninkina 2008). Together, these
ﬁndings suggest that symptoms which are thought to be a
consequence of speciﬁc neurodegenerative processes (e.g.,
injury and death of nigrostriatal dopaminergic neurons), may
result primarily from a gain of toxic function(s) and possibly
partial loss of ASYN’s normal functions. The contribution of
the latter to the disease pathogenesis may increase with
aging.
Other important clues on ASYN pathophysiology came
from the elegant work of Braak and colleagues focusing on
the spreading of Lewy pathology (Braak et al. 1999, 2003;
Braak and Braak 2000). ASYN accumulation was shown to
begin in the lower brainstem (e.g., dorsal motor nucleus of
the vagus nerve) and the olfactory bulb with a subsequent
spreading to the pons, midbrain (including the substantia
nigra) and ﬁnally, mesocortical and cortical areas. Two
signiﬁcant corollaries of these observations are (i) the
concept of a prion-like spreading of ASYN, and (ii) the
view of PD as a ‘whole-brain’ disease. The latter, however,
also emphasizes our need to reconcile what could be
perceived as inconsistent observations. On the one hand,
ASYN is an abundant protein expressed at relatively high
levels (0.5–1% of total neuronal cytosolic protein mass)
(Iwai et al. 1995) throughout the brain. Pathological changes
related to ASYN, such as the formation of Lewy bodies and
of other aggregates consisting of this protein, are found in
many different brain regions. On the other hand, not all
neuronal populations are equally sensitive to the toxic/
pathological consequences of ASYN accumulation and
aggregation (Luk et al. 2012a). A likely explanation for this
apparent inconsistency relates to unique features of the
susceptible neurons and to a speciﬁc ASYN behavior within
these cells.
A clear example of such neuron-type selective events is
provided by DA neurons in the substantia nigra. It has long
been known that a pro-oxidant environment characterizes
these cells because of their DA content (Fahn and Cohen
1992). When dopamine is released from its acidic storage
vesicles either into the synaptic cleft or into the cytosol, it
rapidly undergoes enzymatic and non-enzymatic oxidation
that yields superoxide, dopamine semiquinone radicals,
H2O2, and other oxidants (Graham 1978; Fornstedt et al.
1990). This feature, together with elevated levels of free iron
in the substantia nigra (Dexter et al. 1989), sets the stage for
a Fenton reaction that forms hydroxyl (•OH) radicals and
could result in sustained oxidative stress (Jenner 1991;
Kehrer 2000; Barzilai et al. 2003; Arriagada et al. 2004).
These mechanisms provide a rationale for the high suscep-
tibility of nigral DA neurons to neurodegenerative processes.
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They also raise the critical question of whether oxidative
stress affects ASYN structure/biology and, if so, whether
oxidative damage and ASYN changes could ultimately act
together to trigger or promote ASYN-mediated toxic/patho-
logical events in PD (Fig. 1).
In this review, we will highlight the mutual interactions
between oxidative stress and ASYN, and the inﬂuence of
oxidatively modiﬁed ASYN on membrane binding, mito-
chondrial function and proteostasis, as a basis to explain the
selective neurodegeneration that characterizes PD and related
synucleinopathies. We hypothesize that, at least in certain
neuronal populations, modiﬁed ASYN might be one of the
key ‘links’ between oxidative stress, proteostatic stress,
energy stress, and neurodegeneration. Hence, modiﬁed
ASYN and the enzymes and/or pathways involved in
regulating ASYN modiﬁcations could constitute a potential
target for preventive or curative intervention strategies.
The large family of reactive oxygen and
nitrogen species
The main focus of this review is on oxidative post-
translational modiﬁcations of ASYN and their impact on
the biology of ASYN. Thus, the nature of reactive oxygen
species (ROS) and reactive nitrogen species (RNS), their
sources in a cell, the sites of formation in the brain, as well as
the complex chemistry that is involved, require a thorough
discussion. It is essential to note that low levels of free
radicals, as observed under normal conditions, do not
represent a threat to the cell, and may serve as endogenous
signaling molecules, involved in the regulation of physio-
logical processes (Schildknecht et al. 2005). These condi-
tions, summarized in the literature under the term ‘redox
regulation’ (Frein et al. 2005; Schildknecht and Ullrich
2009) must be clearly separated from conditions of oxidative
stress. The basis for our discussion of ROS and RNS is the
understanding of the chemical properties of nitric oxide
(•NO) and superoxide (•O2
). All other reactive species
discussed here are derived from these two free radicals. A
one-electron reduction of molecular oxygen (O2) leads to the
formation of superoxide (•O2
), which can not only act as
oxidant but also as strong reducing agent. Further reduction
yields hydrogen peroxide (H2O2) and ﬁnally, the hydroxyl
radical (•OH) (Fig. 2).
Although •O2
 is a free radical, its reactivity with
biological structures is relatively low in the cellular context
and it even acts as a reductant. Another important aspect of
•O2
 is its ionic nature that largely prevents its diffusion
across biological membranes at cellular pH. This chemical
property has signiﬁcant biological relevance since •O2
 is
‘trapped’ within the subcellular compartment (e.g., mito-
chondria) where it is formed. At very low pH, •O2
 may be
protonated (pKa = 4.8) and can then cross membranes in the
form of its conjugated acid.
H2O2 reactivity is relatively weak compared with other
ROS such as the •OH radical. Nevertheless, controlling its
effective intracellular levels is highly relevant for the survival
of a cell. In contrast to •O2
, H2O2 can easily cross biological
membranes and together with free ferrous iron, can initiate
Fenton reactions and thus produce the hydroxyl radical (•OH)
(Fenton 1894; Haber and Weiss 1932) (Fig. 3). Among all
ROS, •OH displays the highest reactivity toward biological
structures. As a consequence of its high reactivity with
proteins, lipids, or DNA, it has only a short half-life time and
limited diffusion within a cell (Rodebush and Keizer 1947).
In contrast to •O2
 or H2O2, no enzymatic degradation
systems exist in a cell for •OH. Particularly relevant in the
context of this review are the following considerations: As
already mentioned, DA neurons are at special risk for the
toxic consequences of ROS formation and oxidative reac-
tions. For example, within these neurons, H2O2 could be
generated via both DA autoxidation and monamine oxidase
(MAO)-mediated DA metabolism. H2O2 could more easily
become a substrate for the Fenton reaction because of the
high levels of free iron in the substantia nigra (Olanow
1992). Finally, a continuous cycle of Haber-Weiss and
Fenton reactions could cause substantial oxidation of
proteins (including ASYN) and other macromolecules,
paving the road to degenerative processes.
Fig. 1 Alpha-synuclein (ASYN) as link between oxidative stress,
mitochondria, and proteostasis.
Fig. 2 Formation of reactive oxygen species and mode of action of
cellular defense systems. The one-electron reduction of molecular
oxygen, mediated, for example, enzymatically by NADPH oxidase,
yields superoxide (•O2
). This can act in a cell as oxidant or as
reductant. As selective enzymatic defense systems, the cell contains
cytosolic Cu,Zn- or mitochondrial Mn-superoxide dismutase (SOD).
Further reduction of •O2
 yields hydrogen peroxide (H2O2). This can
either be reduced by cellular glutathione peroxidase or decomposed by
catalase to water and oxygen. One-electron reduction of H2O2 by Fe
2+
or Cu+ yields the highly reactive hydroxyl radical (•OH) for which no
distinct cellular defense system exists.
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Reactive nitrogen species (RNS) are all derived from the
small gaseous molecule nitric oxide (•NO) that is generated
enzymatically from L-arginine in a cell by one of the three
isoforms of nitric oxide synthase (NOS). Neurons express
NOS-1 (= neuronal, nNOS) that, similar to NOS-3 (= endo-
thelial, eNOS) is characterized by a relatively moderate
expression level and cellular activity (Bredt and Snyder
1990; Bredt et al. 1990; Radomski et al. 1990). In contrast
to that, the inducible iNOS (NOS-2) is usually hardly
expressed in the brain under normal conditions, but it can be
up-regulated signiﬁcantly in glial cells by a variety of stimuli
such as inﬂammation, or hypoxia (Radomski et al. 1990).
This isoform leads to the Ca2+-independent formation of high
ﬂuxes of •NO. The main sources of •NO in inﬂamed neuronal
tissue are microglia and astrocytes (Le et al. 2001; Schil-
dknecht et al. 2012b). Although nitric oxide is a free radical,
its direct reactivity with cellular proteins or lipids is
negligible. The interaction between •NO and •O2
 deserves
particular attention in the context of protein modiﬁcations.
Although both radicals are relatively unreactive alone, the
reaction of •NO and •O2
 to form the peroxynitrite anion
(ONOO) is extremely fast (6.7 9 109/M/s), and even
exceeds the dismutation rate of •O2
 by SOD (2 9 109/M/
s) (Beckman and Crow 1993; Huie and Padmaja 1993). This
implies that as soon as •NO and •O2
 are formed within the
same cellular compartment, peroxynitrite is generated. This
reaction product is a strong oxidant that can react by one-
electron oxidations in a radical pathway, and by two-electron
oxidations involving oxygen atom transfer. The radical
pathway is the dominating source for protein tyrosine
nitrations, whereas protein methionine sulfoxidation occurs
by oxygen atom transfer (Souza et al. 1999). In the
discussion of •NO and •O2
 interaction, it has to be noticed
that •NO can freely diffuse across membranes, while •O2

has a very limited capacity to cross lipid bilayers. This
implies that the localization where •O2
 is formed determines
to a large extent the formation of peroxynitrite and conse-
quently the likelihood for tyrosine nitrations in subcellular
compartments. To avoid confusion regarding the designa-
tions of different modiﬁcations, it is important to distinguish
between (i) nitrosylation reactions, in which binding of •NO
to a transition metal in an active site center, such as guanylyl
cyclase, takes place (Arnold et al. 1977); (ii) nitration
reactions that mostly modify tyrosine residues with a
covalently bound NO2 group (Tyr-NO2) (van der Vliet et al.
1995), and (iii) nitrosation reactions that, in a cell, mostly
modify cysteine residues with a covalently bound NO group
(Cys-NO) (Daiber et al. 2009; Ullrich and Schildknecht
2012). Important to note, human ASYN contains no
cysteines.
Methionine sulfoxidation of ASYN
Oxidation of methionines has been observed as a prominent
post-translational modiﬁcation in several proteins for a long
time. In contrast to cysteines, methionines are usually not
directly involved in catalytic centers of enzymes. The
regulatory role of methionine oxidation is rather associated
with structural changes of the respective proteins upon
modiﬁcation. ASYN contains four methionine residues
(Met1, Met5, Met116, Met127), that can be directly oxidized,
for example, by H2O2, peroxynitrite,
•O2
, or •OH (Fig. 4).
Methionine sulfoxidation of ASYN proceeds sequentially.
First, Met5 is oxidized, while Met1, Met116, and Met127
appear to be more protected from oxidation (Zhou et al.
2010). This differential susceptibility may be explained
either by the presence of temporary secondary/tertiary
structures in the mostly unstructured soluble fraction of
ASYN, or by the effect of neighboring amino acids. More
detailed studies on the functional and biochemical conse-
quences of ASYN methionine oxidation have been prevented
by several technical limitations: chemical oxidative modiﬁ-
cations of ASYN always lead to a heterogeneous mixture.
Not only the different methionines can take different
oxidation states but also other amino acids may be oxida-
tively modiﬁed by the methods used in the past. To
circumvent these limitations, new chemical protein synthesis
and semisynthetic approaches were very recently developed
that allow the site-speciﬁc introduction of modiﬁed amino
acids (Hejjaoui et al. 2011, 2012; Butterﬁeld et al. 2012;
Fauvet et al. 2012a). Recently, Maltsev et al. demonstrated
that Met oxidations in ASYN (Met1 and Met5) play an
important role in regulating ASYN membrane binding and
afﬁnity. They also showed that oxidized ASYN is a substrate
for methionine sulfoxide reductase (Maltsev et al. 2013). By
the enzymatic reversibility of its oxidation, ASYN could
Fig. 3 Hydroxyl radical generation by the Fenton reaction. Dopamine
is stable under acidic conditions as observed in neurotransmitter
storage vesicles. At neutral pH in the cytosol or extracellular space, it
rapidly undergoes autoxidation to form dopamine semiquinones. A
redox cycling process of semiquinones and quinones can lead to a
continuous generation of •O2
. This sets the stage for the iron-
catalyzed Haber-Weiss cycle (1). This cycle is the driving force for the
Fenton reaction (2) that leads to the formation of the highly reactive
hydroxyl radical (•OH).
© 2013 International Society for Neurochemistry, J. Neurochem. (2013) 125, 491--511
494 S. Schildknecht et al.
contribute to the protection of membranes from oxidative
damage.
An overview of the aggregation process and the effect of
oxidative modiﬁcations is illustrated in Fig. 5. Oxidation of
methionine residues in ASYN inhibits its ﬁbrillation by
promoting the formation of off-pathway sodium dodecyl
sulfate-resistant stable soluble oligomers that no longer
contribute to the ﬁbrillation process (Leong et al. 2009).
These altered aggregation propensities were observed when
methionine was oxidized by transition metals (Fe2+ or Cu+)
or after treatment of the protein with H2O2 (Cole et al. 2005).
The exact reference to the experimental conditions used is
important, as the structure of ASYN oligomers that originate
upon treatment with different oxidizing agents can vary
signiﬁcantly. For instance, as compared to other toxic
oligomers, stable oligomers formed following H2O2 treat-
ment did not damage DA or GABAegic neurons (Zhou et al.
2010). Given its potential relevance to pathophysiological
processes, the nature and toxicity of oligomers formed
following methionine oxidation of ASYN warrant further
investigation.
Treatment of ASYN with DA or its autoxidation
products leads to an inhibition of ASYN ﬁbril formation
and a concomitant generation of stable ASYN oligomers
(Conway et al. 2001; Li et al. 2004b; Cappai et al. 2005;
Norris et al. 2005; Bisaglia et al. 2010). At least three
mechanisms could explain this ﬁnding at the molecular
level. First, covalently modiﬁed ASYN has been observed
after DA treatment in vitro. However, the low yield, even
under optimized experimental in vitro conditions, indicates
that a signiﬁcant contribution of this type of interaction
under cellular conditions is rather unlikely (Bisaglia et al.
2010).
Fig. 4 Oxidative modiﬁcations of alpha-synuclein (ASYN). The 140
amino acid protein is composed of an N-terminal domain that adopts
an a-helical conformation when in contact to a water-lipid interphase.
The central non-amyloid component (NAC) region is mainly involved in
the aggregation of the protein, while the acidic C-terminal region has
no explicit structural propensity. It serves as regulator of ASYN
structure by intramolecular interactions with the N-terminus (George
2002). Highlighted in bold red characters are the four tyrosines (Y), and
the four methionines (M) that can be nitrated or sulfoxidated.
Fig. 5 Regulation of alpha-synuclein (ASYN) aggregation by oxidative
modiﬁcations. Treatment with peroxynitrite or other oxidants acceler-
ates the formation of covalently linked dimers and/or stable oligomers
that no longer contribute to ﬁbrillation. In contrast, unstable oligomers,
originating from unmodiﬁed ASYN, represent an inhomogenous
mixture of spherical, chain-like, or annular protoﬁbrils. Some of these
transient structures, for example, can form membrane pores and
hence are considered cytotoxic. Nitrated monomeric ASYN alone does
not contribute to ﬁbrillation under conditions that favor ﬁbril formation
by non-modiﬁed ASYN. The situation is different when nitrated ASYN
is added to non-modiﬁed ASYN. In this case, the modiﬁed monomers
serve as aggregation seed (right) and accelerate ﬁbrillation.
© 2013 International Society for Neurochemistry, J. Neurochem. (2013) 125, 491--511
Oxidative modifications of alpha-synuclein 495
Alternatively, non-covalent interactions of DA autoxida-
tion products with ASYN could evoke the observed inhibi-
tion of ﬁbrillation. Interactions between the aromatic ring of
DA (or its oxidation products) with hydrophobic side chains
in the C-terminus of ASYN alters the conformation of ASYN
and thus promotes the formation of small spherical oligomers
(Norris et al. 2005; Mazzulli et al. 2007). This alternative
pathway indirectly prevents the formation of larger aggre-
gates (Herrera et al. 2008). DA shares structural elements
with a large number of chemically synthesized ﬁbrillation
inhibitors, which can undergo oxidation to form quinones.
Interestingly, the great majority of these compounds do not
only prevent the ﬁbrillization of ASYN, but also of other
amyloidogenic proteins, for example, amyloid b peptides
(Conway et al. 2001; Di Giovanni et al. 2010). This
suggests that the actions of DA and its degradation products
may reﬂect a more general principle of how this class of
molecules regulates protein amyloid formation (Conway
et al. 2001).
A third mechanism explaining the actions of DA is based
on the autoxidation of this neurotransmitter, which generates
•O2
, H2O2 and DA semiquinones. These reactive species
could directly oxidize methionines into methionine sulfox-
ides, resulting in an inhibition of ASYN ﬁbril formation
(Uversky et al. 2002; Hokenson et al. 2004; Leong et al.
2009; Zhou et al. 2009). Mutation of methionine residues to
alanine in ASYN blocked the formation of DA-induced SDS-
resistant stable soluble oligomers (Leong et al. 2009),
suggesting that methionine oxidation plays a critical role in
DA-mediated oligomer formation. Moreover, it is possible
that DA byproducts interact directly with ASYN oligomers
and prevent their transition into mature ﬁbrils. What makes
the oxidation of methionines unique in comparison with
other oxidative modiﬁcations, such as nitration of tyrosines,
is the existence of a cellular defense system against
methionine oxidation. Methionine sulfoxide reductase
(Msr) is an enzyme that catalyzes the reduction of oxidized
methionines back to their normal state (Yermolaieva et al.
2004; Wassef et al. 2007; Liu et al. 2008) (Fig. 6). Msr is
present in two isoforms, that is, Msr A and Msr B, with Msr
A being expressed in the nervous tissue. The catalytic
activity of methionine sulfoxide reductase within neurons
expressing this enzyme makes methionine oxidation a
reversible and controlled process (Moskovitz 2005). In fact,
one may even speculate that this catalytic function, when
applied on ASYN, may confer a role of oxidant scavenger to
this protein. Reactive •OH, semiquinones and other radical
species, when present within the cytosol of neuronal cells,
could readily react with methionine residues of ASYN. Then,
Msr activity would be capable of repairing this oxidative
damage (Maltsev et al. 2013). Such a sequence of molecular
events, if demonstrated experimentally, would provide
evidence for a ROS-scavenging contribution of ASYN under
physiological conditions and, possibly, during very initial
stages of PD. In early PD, at a time when the glia-dependent
production of •NO-derived reactive species has yet to be
induced (see below), the balance between ROS and RNS
formation may favor •O2
 and its derivatives and therefore
facilitate ASYN-methionine oxidation/reduction reactions.
Tyrosine nitration and di-tyrosine formation of
ASYN
Nitration of protein tyrosine residues is a classical hallmark
of most pathophysiological conditions (Duda et al. 2000).
There are several examples in the literature indicating that
nitration can alter the activity and structure of ASYN and
other proteins (Giasson et al. 2000; Ischiropoulos 2009;
Schildknecht et al. 2012a). ASYN is a prominent target for
peroxynitrite-mediated nitration (Fig. 4) and nitrated ASYN
has even been suggested as clinical biomarker for the
diagnosis of PD (Fernandez et al. 2013). Recent work also
(a)
(b)
Fig. 6 Chemical biology of tyrosine nitration and methionine sulfoxi-
dation. (a) Tyrosine nitration is an irreversible reaction. At cellular pH,
most peroxynitrite is present in its deprotonated form, but peroxyni-
trous acid (ONOOH) is formed rapidly by protonation (pKa = 6.6). It is
chemically unstable and undergoes homolysis into the •NO2 radical
and the hydroxyl radical (•OH). The •OH or the •NO2 radical can react
with tyrosine residues to form tyrosyl radicals. In the presence of large
amounts of bicarbonate, peroxynitrite can also react with CO2. Two
thirds of the resultant reaction product decomposes to yield nitrite
(NO2
) and CO2 (2), while about one third generates the
•NO2 radical
and CO3
• (3). The •NO2 from (1) and (3) can react with the tyrosyl
radical to form 3-nitrotyrosine (3-NT). (b) Methionine oxidation is a
biologically reversible reaction. The reduction of methionine sulfoxide
is catalyzed by methionine sulfoxide reductase (Msr). This enzyme
uses the thioredoxin reductase (TrxR)-thioredoxin (Trx) system, driven
by NADPH for its enzymatic oxidation–reduction cycle.
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underscores an intriguing relationship between PD risk
factors and ASYN nitration. Aging is perhaps the only
unequivocal risk factor for idiopathic PD. Interestingly, the
substantia nigra of the aging primate brain is characterized
by enhanced levels of soluble ASYN (Li et al. 2004a; Chu
and Kordower 2007) and by increased levels of post-
translationally modiﬁed ASYN, including nitration (Giasson
et al. 2000; McCormack et al. 2012). Another potential PD
risk factor is exposure to environmental toxins (Vieregge
et al. 1988; Di Monte 2003). Experimental models repro-
ducing toxicant-induced injury of nigrostriatal dopaminergic
neurons also feature an up-regulation of ASYN as well as
formation of nitrated ASYN (McCormack et al. 2008).
Taken together, these ﬁndings suggest that ASYN nitration is
a marker of increased neuronal vulnerability to degenerative
processes and may itself contribute to pathogenic events
underlying human synucleinopathies.
About 20–30% of peroxynitrite (ONOO) is present in its
protonated form peroxynitrous acid (ONOOH) under phys-
iological pH conditions (Goldstein and Czapski 1995;
Kissner et al. 1997). Peroxynitrous acid dissociates readily
into the highly reactive •OH radical and the nitrogen dioxide
radical (•NO2) that represents the actual nitrating species
(Pr€utz et al. 1985; Merenyi et al. 1998). A more sophisti-
cated view on the chemistry of peroxynitrite-mediated
tyrosine nitrations includes the role of carbon dioxide/
bicarbonate that is present in cells in the millimolar
concentration range, that is, several orders of magnitude
higher than steady-state peroxynitrite levels (Goldstein et al.
2001) (Fig. 6). The interaction of ONOO and CO2 has a
sufﬁciently high rate constant (2.9 9 104/M/s) to consider it
as one of the dominating pathways for peroxynitrite decom-
position in biological systems (Lymar and Hurst 1995; Uppu
et al. 1996). The intermediate ONOOCO2
- was shown to
decompose partially into •NO2 and CO3
• (Bonini et al.
1999; Goldstein et al. 2001). While •NO2 is the predominant
nitrating species, formation of a tyrosyl radical is a second
prerequisite for the occurrence of tyrosine nitration. Forma-
tion of tyrosyl radicals through interaction with •OH, CO3
•,
or •NO2 not only sets the stage for the nitration by the
•NO2
radical but alternatively can also lead to the formation of
covalent di-tyrosine bonds (Pfeiffer et al. 2000; Souza et al.
2000) (Fig. 7). At lower peroxynitrite levels, or at higher
substrate levels, a shift from tyrosine nitration to tyrosine
dimer formation could be expected, as the likelihood for two
tyrosyl radicals to encounter each other is increased. The
strong concentration-dependence and the short half-life time
of its intermediates limit the incidence for di-tyrosine
formation for most proteins in a cell. The situation is
different for ASYN. Its high abundance in the cytosol would
favor di-tyrosine formation between ASYN monomers, and
the end-product has been observed both in vitro and in vivo
(Souza et al. 2000). The precise position of the respective
tyrosines involved in the di-tyrosine formation is still
unclear, but preliminary data from our group suggest a
preferred role of Y39 in di-tyrosine formation. We observed
that Tyr39 was relatively resistant to nitration (Schildknecht
et al. 2011), and an ASYN mutant, lacking the three C-
terminal tyrosines, was resistant to nitration but rather formed
SDS- and heat-stable ASYN dimers (Gerding et al., unpub-
lished). The pathogenic A30P and A53T mutants exhibited
an increased propensity for dimer formation via di-tyrosine
formation, most likely because of their greater propensity to
self-interact (Narhi et al. 1999; Kang and Kim 2003).
Theoretically, all potential di-tyrosine combinations between
two ASYN monomers may be formed. A preference for
deﬁned combinations however appears as a more likely
scenario since the di-tyrosine formation process is in
competition with the nitration of tyrosines. A simultaneous
involvement of a single tyrosine residue both in the
formation of a di-tyrosine dimer as well as a target for
(a) (b)
(c)
Fig. 7 (a) Mechanism of tyrosine nitration and di-tyrosine formation.
Tyrosine is oxidized to form an instable tyrosyl radical by various
oxidants. In the presence of the •NO2 radical, nitration via a radical-
based mechanism takes place. Alternatively, when two tyrosyl radicals
encounter each other, a covalent di-tyrosine bond can be formed. (b)
For the western blots, puriﬁed alpha-synuclein (ASYN) was treated
with peroxynitrite as indicated. The membranes were stained with an
anti-ASYN, or with an anti-3-nitrotyrosine (3-NT) antibody. Peroxyni-
trite caused nitration of the ASYN monomer. In parallel, a second band
with the mass of two ASYN monomers appears. This dimer also
exhibited tyrosine nitration. (c) Nitrated ASYN is observed in the aging
brain (McCormack et al. 2012), Parkinson’s disease (PD) (Giasson
et al. 2000), or during experimental neurodegeneration (McCormack
et al. 2008). As an example, dopaminergic neurons in the substantia
nigra of a squirrel monkey, treated with MPTP, are shown. Widespread
immunoreactivity (brown) for nitrated ASYN is detected. The darker
dots within neurons represent neuromelanin. The tissue was obtained
from an animal four weeks after a single subcutaneous injection of
1.75 mg/kg MPTP. Scale bar = 10 lm.
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nitration cannot be excluded completely, but from a chemical
point of view, appears less likely.
Influence of oxidative modifications on the
toxicity of ASYN
The central role of ASYN in the pathogenesis of PD and
other synucleinopathies raises the question on how oxidative
modiﬁcations affect its toxicity. The best-characterized
mechanisms of ASYN cytotoxicity are associated with the
protein’s tendency to undergo aggregation. For instance,
protoﬁbrillar forms of ASYN were shown to bind to
membranes and cause membrane permeabilization via pore-
like mechanisms or enhanced ﬂip-ﬂop of membrane lipids
(Volles et al. 2001; St€ockl et al. 2011). Prominent examples
are neurotransmitter vesicles that become leaky (Lotharius
et al. 2002) or mitochondria that display impaired function
upon protoﬁbril binding (Hsu et al. 2000; Parihar et al.
2008; Kamp et al. 2010). The processes of aggregation and
membrane binding are discussed in detail in the following
sections.
Oxidatively modiﬁed ASYN has been shown to inhibit not
only its own degradation by chaperone-mediated autophagy
(CMA), but also that of other proteins (Martinez-Vicente
et al. 2008; Xilouri et al. 2009). As a result of these events,
an imbalance between the formation and degradation of such
proteins occurs. This does not only result in the accumulation
of misfolded proteins but allows an elevation of normal
functional proteins. This has for instance been shown for the
transcription factor Mef2D (Yang et al. 2009). The effect of
aggregation-prone proteins on cellular levels of unrelated
proteins may be a general principle, that is also known from
Huntington’s disease, where huntingtin can inﬂuence the
transcription machinery and hence inﬂuence cellular pro-
cesses (Steffan et al. 2000; Nucifora et al. 2001; Schaffar
et al. 2004; Cui et al. 2006). Although the cytotoxic
mechanisms discussed so far relate to intracellular events,
different pathophysiological mechanisms may be associated
with extracellular ASYN, excreted from neurons via exocy-
tosis and/or release after neuronal injury (El-Agnaf et al.
2006; Tokuda et al. 2010; Hansen and Li 2012). Elevated
levels of extracellular ASYN initiate microglial activation
that in turn leads to the release of pro-inﬂammatory cytokines
(Zhang et al. 2005; Lee et al. 2010; Fellner et al. 2013).
Relevant for our discussion on the impact of oxidative
modiﬁcations of ASYN is the observation that nitrated
ASYN can activate microglia via the integrin receptor a5b1
(Liu et al. 2011). An inﬂammatory activation of microglia
subsequently leads to a secondary activation of astrocytes
(Giulian et al. 1994) and both cell types can form relatively
large ﬂuxes of ROS and RNS. These free radical species can
directly lead to damage of adjacent neurons (Le et al. 2001)
and trigger the nitration of so far unmodiﬁed ASYN (Gao
et al. 2008). In addition to the direct activation of microglia,
ASYN also stimulates the adaptive immunological response
(Benner et al. 2008; Theodore et al. 2008; Stefanova et al.
2011). Nitration of ASYN hence leads to a breakage of
immunological tolerance because of the generation of a new
antigen unknown to the immune system. Nitrated ASYN
induces proliferation and activity of speciﬁc effector T cells
that contribute to the degeneration of DA neurons in the
substantia nigra. Interestingly, Reynolds et al. observed a
protective role of regulatory T cells in ASYN-NO2-mediated
adaptive T-cell response. In this study, vasoactive intestinal
peptide (VIP) was used as an adjuvant known to boost the
regulatory T-cell response. Results suggest that an immune
response to ASYN is not necessarily detrimental; vaccination
strategies, however, could dampen the adverse effects of an
immune response directed toward nitrated ASYN in the brain
(Reynolds et al. 2010).
Influence of oxidative modifications on
membrane binding of ASYN
General interaction of ASYN with membranes
ASYN is an intrinsically disordered protein. While it is
considered unstructured in solution, it can undergo confor-
mational changes to form an N-terminal alpha-helical region
and an unstructured C-terminal domain when it binds to a
water-lipid interface with a negative net charge (Davidson
et al. 1998; Eliezer et al. 2001) (Fig. 8). Most of the initial
studies on conformational changes upon lipid binding have
been performed with deﬁned artiﬁcial vesicles in which lipid
composition and diameter can be regulated as desired. These
investigations revealed that ASYN preferentially binds to
phospholipids with a negatively charged head group such as
sphingomyelin, phosphatidylserine, or phosphatidylglycerol.
Fig. 8 Inﬂuence of nitration on alpha-synuclein (ASYN) biology. ASYN
contains four tyrosine residues and is a preferred target for nitration in
a cell. Nitrated ASYN displays different properties compared with the
unmodiﬁed form. These altered properties could contribute to the
toxicity of ASYN as observed in various synucleinopathies.
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The lipid interaction occurs via the N-terminal region of
ASYN (Kubo et al. 2005; Beyer 2007). Furthermore, ASYN
preferentially interacts with highly curved membranes, as
indicated by the observation that intracellular ASYN binds
preferentially to small and highly curved structures such as
vesicles or mitochondria (Davidson et al. 1998; Nuscher
et al. 2004). When bound to small artiﬁcial micelles
(diameter ~ 5 nm), ASYN forms a horse-shoe like structure
whereas it binds to more physiological lipid vesicles with
diameters > 100 nm as an elongated helix parallel to the
curved membrane (Jao et al. 2004, 2008; Borbat et al.
2006). This behavior allows conserved lysine and glutamate
residues to interact with dipolar headgroups, while uncharged
amino acid residues penetrate into the acyl chain region (Jao
et al. 2004, 2008). Recently, direct evidence of coexisting
horseshoe and extended helix conformations of membrane-
bound ASYN has been reported (Robotta et al. 2011). At
high ASYN/lipid ratios, ASYN is capable of remodeling
lipid vesicles, for example, large spherical vesicles can be
converted into cylindrical micelles of ~ 50 A in diameter
(Mizuno et al. 2012). Rather surprisingly, the outermost
8–10 N-terminal amino acids are absolutely essential for
membrane binding, as deletion of this peptide sequence
results in a complete loss of membrane binding (Vamvaca
et al. 2009; Robotta et al. 2012). The relevance of the N-
terminal region for membrane binding is further underlined
by the observation that N-terminal acetylation results in an
increase in a-helicity of the ﬁrst 12 residues when free in
solution. N-terminally acetylated ASYN also exhibits
increased lipid binding afﬁnity, since pre-formation of an
a-helix in aqueous solution signiﬁcantly increases the on-rate
while not signiﬁcantly affecting the off-rate (Maltsev et al.
2012). Interestingly, the A30P, but not A53T mutant has an
elevated off-rate from the membrane, compared to the wild-
type protein, which is most likely because of the disruption
of one of the N-terminal a-helices by the proline (Jensen
et al. 1998).
Studies using artiﬁcial lipid vesicles revealed that mem-
brane binding prevents ASYN from aggregation (Zhu and
Fink 2003; Uversky and Eliezer 2009). When ASYN was
added to brain membrane preparations, membrane-bound
ASYN was identiﬁed as seeding nucleus for the aggregation
of unbound ASYN monomers (Lee et al. 2002). A potential
explanation for these apparently discrepant observations
could be the presence of cytosolic proteins. Indeed, cytosolic
proteins from brain were identiﬁed to trigger the dissociation
of membrane-bound ASYN (Wislet-Gendebien et al. 2006).
It could hence be speculated that ASYN aggregation is
prevented in systems of artiﬁcial vesicles by tight binding of
protein monomers to the membranes. In the presence of
cytosolic proteins, structural changes in ASYN monomers
may occur on the membrane. These could promote the
formation of soluble, instable oligomers that are prerequisite
for ﬁbril formation.
Alterations in membrane binding through post-transla-
tional modiﬁcations may play a particularly important role in
neuronal cells with a cytosolic ASYN content of up to 0.5–
1% (Iwai et al. 1995), and with a high surface-to-volume
ratio, as in dendrites or axons. For instance, C-terminal
phosphorylation does not alter membrane binding (Paleolo-
gou et al. 2008), whereas phosphorylation at S87 in the
central NAC region, interferes with membrane binding
(Paleologou et al. 2010). Mechanisms by which post-trans-
lational oxidative modiﬁcations may alter ASYN membrane
interactions and therefore contribute to ASYN’s pathological
role are discussed in detail below.
Influence of oxidative modifications on ASYN membrane
binding
Apparently, selective nitration at position Tyr39, that is,
within the lipid interaction region, has been shown to
decrease ASYN binding to membranes (Hodara et al. 2004;
Danielson et al. 2009) (Fig. 8). The effect may be because of
electrostatic repulsion of the negatively charged nitrotyrosine
and the negatively charged lipids. As a consequence,
nitration would result in elevated levels of free ASYN
(Hodara et al. 2004). Aggregation of ASYN into cytotoxic
protoﬁbrils is dependent on the actual concentration of
soluble ASYN (Kim and Lee 2008). Furthermore, nitrated
ASYN monomers and dimers were shown to trigger
ﬁbrillation of unmodiﬁed ASYN (Hodara et al. 2004). The
decrease of membrane binding by nitration could therefore
increase the tendency to form ﬁbrils. N-terminal tyrosine
nitration of ASYN would prevent the inhibitory effect that
membrane binding has on ASYN aggregation (Narayanan
and Scarlata 2001; Zhu and Fink 2003). Interestingly, not
only nitration of the N-terminal Tyr39 but also nitration of the
tyrosines at the C-terminal end (Y125, Y133, Y136) that are
positioned outside the membrane binding region, leads to a
signiﬁcant reduction in membrane binding (Sevcsik et al.
2011). As explanation, a change in the global structure of
ASYN upon nitration that also inﬂuences the conformational
properties of the N-terminal region was assumed (Sevcsik
et al. 2011). This observation is of particular relevance with
regard to the ﬁnding that ASYN nitration at low peroxynitrite
levels typically starts at the C-terminal tyrosine residues
(Schildknecht et al. 2011). Such conditions are likely to be
found in inﬂamed brain tissue with activated glial cells.
Hence, it is possible that the reduced membrane binding of
nitrated ASYN leads to an increased concentration of free
ASYN. This may ultimately result in an increased tendency
to form ﬁbrils; however, experimental evidence in cells is
currently not yet available.
Regulation of mitochondrial fission and fusion by ASYN
Scientiﬁc interest in the interaction of ASYN with biological
membranes, lipid metabolism, and mitochondria was aroused
by initial ﬁndings in yeast models (Outeiro and Lindquist
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2003; Willingham et al. 2003) showing that some disease-
mimicking conditions, such as increasing protein concentra-
tions or introducing the disease mutation A30P, resulted in
signiﬁcant disruption of membrane binding and redistribu-
tion of ASYN from the membrane to the cytosol. After it was
discovered that ASYN undergoes signiﬁcant conformational
changes when it gets in contact with a water-lipid interface
(Jao et al. 2004; Ulmer et al. 2005), it became obvious that
ASYN prefers acidic phospholipids and certain lipid domain
structures for optimal binding (Fortin et al. 2004). Based on
these ﬁndings, it was suggested that ASYN is a modulator of
synaptic vesicle trafﬁcking and a regulator of vesicle fusion
with the pre-synaptic membrane (Lotharius et al. 2002).
Indeed, mice lacking ASYN, or mice with a knockdown of
a-, b-, and c-synuclein, display an increased DA release that
correlated with an increased tendency of neurotransmitter
vesicles to fuse with the pre-synaptic membrane (Abeliovich
et al. 2000; Yavich et al. 2004; Anwar et al. 2011). In
contrast, ASYN over-expression led to an impaired neuro-
transmitter release and an accumulation of neurotransmitter
vesicles at the plasma membrane that were prevented from
fusion (Garcia-Reitb€ock et al. 2010; Nemani et al. 2010;
Scott et al. 2010).
It also became evident that the propensity of ASYN to
interact with membranes could be relevant to mitochondrial
function. A potential physiological role of ASYN in
mitochondria is suggested by ﬁndings indicating that the
32 N-terminal amino acids of ASYN contain a cryptic
mitochondrial targeting signal (Devi et al. 2008), as well as
by studies in which a complete knockdown of endogenous
ASYN expression resulted in an impaired respiratory capac-
ity and an inadequate spatial extension between components
of the respiratory chain (Ellis et al. 2005). Mitochondrial
impairment has long been hypothesized to contribute to PD
pathogenesis (Santos and Cardoso 2012). Thus, ASYN-
membrane interactions provide an intriguing mechanistic link
between ASYN expression/accumulation, mitochondria
pathophysiology and PD development.
The morphology of mitochondria is continuously changing
in a cell. This does not only involve normal growth and
shape changes but also mitochondrial ﬁssion and fusion. The
latter events are dynamic processes involved in the quality
control and maintenance of these organelles (Youle and van
der Bliek 2012). In mitochondria, fusion requires the
formation of a so-called fusion-stalk, an area with pro-
nounced curvation of the membranes (Nuscher et al. 2004;
Kamp and Beyer 2006; Kamp et al. 2010; Nakamura et al.
2011). Over-expression of ASYN results in an increased
fragmentation of mitochondria, concomitant with a decline in
cellular respiration and ultimately neuronal death (Nakamura
et al. 2011). The fragmentation observed under these
conditions does not require the ﬁssion protein Drp1. This
suggests a direct interaction of ASYN with mitochondrial
membranes (Nakamura et al. 2011). In the seminal work of
the Haass and Berger laboratories, it was discovered that
ASYN preferentially binds to sites of disordered membrane
structures that occur under conditions of high curvature,
found for example, in synaptic vesicles, but also in the
fusion-stalks (Kamp et al. 2010; Nakamura et al. 2011). By
binding to these sites, ASYN seals the packing defects and
hereby inhibits the formation of a mitochondrial fusion,
ultimately leading to an elevated rate of mitochondrial
fragmentation. These observations were further conﬁrmed by
a siRNA-mediated knockdown of ASYN, which results in
elongated mitochondria (Kamp et al. 2010). The described
activity may be of pathological relevance, as ASYN-
inhibited fusion is restored by the PD-linked genes parkin
and PINK1 in their wild-type form, but not by the PD-related
mutants (Exner et al. 2007, 2012; Lutz et al. 2009).
No experimental evidence for the role of oxidative
modiﬁcations on the regulatory function of ASYN in the
ﬁssion/fusion process exists so far. For ASYN tyrosine
nitration, decreased binding to membranes has been docu-
mented (Hodara et al. 2004). Based on these ﬁndings, it
could be speculated that nitration of ASYN might allow
higher rates of mitochondrial fusion and favor neurotrans-
mitter vesicle fusion with the pre-synaptic membrane upon
stimulation. More work on the interaction of modiﬁed ASYN
with mitochondria is required, as ASYN not only affects
mitochondrial ﬁssion and fusion but also can inﬂuence
respiration by its binding to the inner mitochondrial mem-
brane (Devi et al. 2008; Loeb et al. 2010). Investigating the
impact of oxidative modiﬁcations on ASYN’s regulatory role
in mitochondrial physiology may therefore open a promising
ﬁeld of research on a highly relevant aspect in PD. An effect
of ASYN on mitochondrial function may explain why
impaired mitochondrial respiration and ATP generation are
frequently observed in PD patients (Schapira et al. 1990;
Arduıno et al. 2011).
Effect of oxidative modifications on ASYN
aggregation
General aspects on oligomerization and fibrillation of ASYN
Full length ASYN and ASYN-derived peptides were orig-
inally discovered as the main components of Lewy bodies in
PD and other neurodegenerative diseases (Spillantini et al.
1997). These observations per se indicate a strong tendency
of this protein to form aggregates. Different states and forms
of protein aggregation have been described differently in the
literature. Here, we will use a combination of recently
proposed deﬁnitions (Fink 2006; Breydo et al. 2012; Lashuel
et al. 2013). In the beginning of all these pathways, ASYN
exists primarily as an unstructured polypeptide chain (Fauvet
et al. 2012b). In a process that is affected, for example, by
temperature, pH, protein concentration, ions, or stirring, the
unfolded ASYN undergoes conformational changes to
partially adopt a b-sheet structure that is a prerequisite for
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ﬁbril formation. (Uversky et al. 2001a Uversky et al. 2001b)
(Fig. 8). A key feature of in vitro ASYN ﬁbrillation is a lag
phase that is characterized by the formation of transient and
unstable oligomers from which monomers can still disas-
semble (Wood et al. 1999). During this lag phase, a critical
nucleus needs to be formed ﬁrst that can then serve as ‘seed’
for the formation of larger ﬁbrils by the addition of ASYN
monomers. Protoﬁbrils, that are routinely described in the
literature, are also transient species and represent ASYN
oligomers of heterogenous size and morphology distribution.
Spherical, chain-like and annular protoﬁbrils have been
observed as intermediates during the ﬁbrillization of ASYN
in vitro (Conway et al. 2000; Ding et al. 2002; Lashuel
et al. 2002a, b). In contrast to these highly variable and
dynamic oligomeric structures, ﬁbrils are deﬁned as elon-
gated structures with a cross-b-sheet conﬁguration that gain
size by addition of monomers to the growing end of the ﬁbril.
Because of the ﬂexibility of transient oligomers, monomers
can disassemble from these complexes and then contribute to
ﬁbril formation. Transient oligomers can furthermore directly
contribute to ﬁbril elongation by longitudinal association
with a ﬁbril (Fink 2006). In contrast to the formation of
transient oligomers from unmodiﬁed ASYN monomers,
oxidatively modiﬁed ASYN monomers can form stable
oligomers (Hokenson et al. 2004; Uversky et al. 2005; Qin
et al. 2007). Such stable oligomers also contain unmodiﬁed
monomers and are formed more readily than ﬁbrils under
conditions of oxidative stress. Disassembly of ASYN
monomers from these stable oligomers only hardly takes
place, and consequently, these monomers can no longer
contribute to ﬁbril elongation (Uversky et al. 2002; Yamin
et al. 2003; Zhu et al. 2004). The formation of stable
oligomers, occurring mostly under conditions of oxidative
stress, represents therefore an off-pathway redirection of
ASYN monomers to oligomer, instead of ﬁbril formation.
Influence of oxidative modifications on ASYN
oligomerization and fibrillation
Analysis of ASYN obtained from Lewy bodies of PD brains
revealed a wide array of post-translational modiﬁcations,
including nitration of tyrosines, oxidation of methionines,
covalent modiﬁcation of histidines and lysines by 4-hydroxy-
2-nonenal (HNE), and many others, such as phosphorylation,
ubiquitination, or SUMOylation. The contribution of such
modiﬁcations to the aggregation properties of ASYN are an
area of intensive investigation.
Nitration of ASYN leads to the stabilization of a partially
folded conformation of the monomer and inhibits its
ﬁbrillization by stabilizing off-pathway oligomers (Yamin
et al. 2003; Kaylor et al. 2005; Uversky et al. 2005). In such
oligomers, not only nitrated ASYN monomers but also
covalent di-tyrosine cross-links between monomers can be
found. This makes the oligomers formed by nitrative insult
extremely stable (Souza et al. 2000). When reviewing
literature data on the nitration of ASYN and its impact on
ﬁbrillation, it is essential to discriminate between experi-
mental nitration conditions leading to a mixture of un-
modiﬁed ASYN, nitrated ASYN monomers, dimers, and
oligomers, and studies working with puriﬁed nitrated ASYN
monomer (Souza et al. 2000; Hodara et al. 2004). Addition
of high concentrations of nitrated ASYN species to unmod-
iﬁed ASYN leads to inhibition of ﬁbrillation. (Uversky et al.
2005) (Fig. 5). In contrast, when puriﬁed nitrated ASYN
monomer or dimer is added in sub-stoichiometric concen-
trations to unmodiﬁed ASYN monomers, the nitrated
monomers and dimers, which are characterized by a partially
folded conformation, trigger the formation of ﬁbrils from
unmodiﬁed ASYN by serving as ﬁbrillation seed (Hodara
et al. 2004). This seeding effect is clearly different from the
ﬁbrillation process as such, as puriﬁed nitrated ASYN
monomers and dimers alone were no longer able to form
ﬁbrils (Fig. 5).
Similar to the nitration of tyrosines, methionine sulfoxi-
dation can also affect ﬁbrillation of ASYN. Oxidation of
methionines in ASYN prevents the formation of ﬁbrils and
instead promotes the formation of stable oligomers (Hoken-
son et al. 2004; Cole et al. 2005; Zhou et al. 2010).
Methionine-oxidized ASYN, when present in excess, can
also prevent unmodiﬁed ASYN from contributing to the
ﬁbrillation process by sequestering the unmodiﬁed mono-
mers into the already formed oligomers or poising ASYN
oligomer growth and ﬁbril formation (Uversky et al. 2002).
It is important to note that all data cited above were generated
with oxidized ASYN that was used without further puriﬁ-
cation after the oxidation procedure. Chemical oxidative
modiﬁcations of ASYN always lead to a heterogeneous
mixture of ASYN species with variable modiﬁcation
patterns. Furthermore, treatment with oxidants can lead to
the generation of covalently linked ASYN dimers and
multimers. So far, no information is available on the
aggregation properties of molecularly deﬁned ASYN mono-
mers with oxidized methionines at speciﬁc positions. This is
mainly because of the lack of methodologies that allow site-
speciﬁc oxidative modiﬁcations of ASYN, a limitation that
has been addressed by recent advances made by the
development of chemical and semisynthetic strategies for
preparing ASYN (Hejjaoui et al. 2011, Hejjaoui et al. 2012;
Fauvet et al. 2012b).
Under conditions of oxidative stress, lipid peroxidation
takes place and leads to the generation of reactive aldehydes,
among them, 4-hydroxy-2-nonenal (HNE), is routinely
detected. It is a marker of lipid peroxidation in a variety of
experimental and pathological conditions, including neuro-
degenerative diseases (Yoritaka et al. 1996). HNE covalently
binds to histidine and lysine residues and triggers the
formation of b-sheet rich ASYN oligomers (Bae et al. 2013).
Similar to the nitration of tyrosines or the oxidation of
methionines, HNE modiﬁcations prevent ﬁbrillation by
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promoting the formation of off-pathway oligomers (Qin
et al. 2007; Bae et al. 2013).
These three examples of oxidative modiﬁcations of ASYN
illustrate a re-direction of ASYN monomers from the
preferred ﬁbrillation pathway into the alternative off-pathway
that results in the formation of stable oligomers. Interest-
ingly, the PD mutations have also been shown to promote the
formation of off-pathway aggregates in addition to the
ﬁbrillization competent ASYN oligomers (Conway et al.
2000). Whether the oligomer formation route represents a
protective or cytotoxic mechanism, remains to be investi-
gated. Oligomers formed from mutated ASYN are toxic in
rodents (Winner et al. 2011). It is important to note that the
oligomers formed upon oxidative treatment do not represent
one deﬁned species but rather a heterogeneous mixture of
oligomers of variable sizes and morphologies. This variabil-
ity, combined with differences in the pattern of oxidation,
could explain the difference in terms of toxic properties
observed for oligomers prepared under different oxidative
conditions; for instance, some reports indicate that methio-
nine-oxidized oligomers are not harmful to neuronal cells
(Zhou et al. 2010), while other investigations show that
HNE-modiﬁed oligomers are highly cytotoxic (Qin et al.
2007; N€asstr€om et al. 2011a).
Influence of oxidative modifications on ASYN
degradation
Genetic observations showing a causal association between
familial parkinsonism and ASYN multiplication mutations
suggest that any molecular or cellular changes (e.g., aging
and toxic exposures) that lead to increased ASYN levels
could promote deleterious consequences (Ulusoy and Di
Monte 2012). The toxic potential of increased ASYN levels
also underscores the importance of intraneuronal mecha-
nisms regulating ASYN homeostasis through its synthesis
and degradation. Clearance of ASYN can occur via the
ubiquitin-proteasome system (UPS) as well as via lysosomal
pathways. It has been suggested that the former may be more
relevant under physiological conditions, while the latter
could play a more prominent role in pathology (Ebrahimi-
Fakhari et al. 2011, 2012). Such a distinction, however, may
not be as clear-cut. Intriguing evidence indicates that
oxidative modiﬁcations of ASYN can inﬂuence its degrada-
tion. While normal ASYN monomers can be degraded by the
20S proteasome (Tofaris et al. 2003), this process was
slowed down signiﬁcantly by nitration of ASYN (Hodara
et al. 2004). In addition, ASYN oligomers, generated under
nitrating conditions, inhibit proteasome activity (Lindersson
et al. 2004). Moreover, oxidation/nitration of ASYN can
lead to its C-terminal truncation by the proteasome, instead
of complete degradation (Mishizen-Eberz et al. 2005).
Truncated forms of ASYN are frequently found in PD
brains; they aggregate much faster than wild-type ASYN and
can even act as aggregation seed for normal, unmodiﬁed
ASYN (Li et al. 2005; Ulusoy et al. 2010).
ASYN contains a target motif (KFERQ) for chaperone-
mediated autophagy (CMA) that allows its recognition by the
heat shock cognate protein of 70 kDa (hsc70) and its
translocation into lysosomes for degradation (Vogiatzi et al.
2008; Mak et al. 2010). The seminal work of Cuervo and
colleagues (Cuervo et al. 2004) also demonstrated that
mutant forms of ASYN (A53T and A30P) bind to the
CMA lysosomal receptor LAMP-2A but, instead of gaining
access into the lysosomal lumen, act as uptake blockers
preventing their own degradation and the degradation of
other CMA substrates (Cuervo et al. 2004). Interestingly,
oxidative modiﬁcations of wildtype ASYN can induce
similar effects; in particular, DA-modiﬁed ASYN has been
shown to block protein clearance through CMA (Martinez-
Vicente et al. 2008). One consequence of the inhibition of
CMA by modiﬁed ASYN is likely to be the induction of
macroautophagy. Macroautophagy could also play a critical
role under conditions favoring the formation of large
aggregates of ASYN, which cannot be cleared via UPS or
CMA.
Taken together, experimental data concerning the effects
of oxidatively modiﬁed ASYN on the UPS and CMA raise
the possibility of the following scenario: The formation of
nitrated and DA-modiﬁed ASYN could lead to impaired UPS
and CMA activity that would in turn decrease the clearance
of unmodiﬁed ASYN. Enhanced ASYN levels would then
favor further production of modiﬁed ASYN forms, giving
rise to a vicious cycle of protein accumulation and oxidation.
Neuronal damage may result from this protein load and could
be compounded by an enhanced tendency of ASYN to
aggregate and an overall blockage of protein degradation
pathways.
Intercellular spreading of ASYN – role of
oxidative modifications
One of the most interesting developments in recent years of
PD research concerns the transmission of ASYN between
cells, resulting in a prion-like spreading of the protein (Braak
et al. 2003; El-Agnaf et al. 2003; Kordower et al. 2008;
Desplats et al. 2009). A critical observation was made in PD
patients who had received transplants of healthy neurons;
after a period of 11–22 years, these transplanted neurons
displayed extensive ASYN pathology in the form of Lewy
bodies, suggesting spreading of the pathology from the
patient to the donor cells (Li et al. 2008, 2010). Both
exocytosis and uptake of ASYN, as well as spreading of
ASYN pathology, have been observed in cell cultures and
rodent models (Lee et al. 2005; Luk et al. 2012a, b).
Moreover, ASYN monomers and oligomers are present in
the cerebrospinal ﬂuid (Borghi et al. 2000). Exocytosis
of ASYN was originally interpreted as an alternative
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mechanism for a cell to cope with excessive ASYN levels
(El-Agnaf et al. 2003). At ﬁrst glance, this appears as an
elegant way to lower intracellular ASYN levels. However,
three additional aspects have to be taken into account: (i)
extracellular ASYN is cleaved by extracellular matrix
metalloproteinases (MMP’s) (Sung et al. 2005) to form
truncated, highly aggregation-prone ASYN products; (ii)
extracellular ASYN leads to an inﬂammatory activation of
glial cells associated with NOS-2-dependent •NO formation
that leads to peroxynitrite generation and promotes nitration
of ASYN and other proteins (Reynolds et al. 2008, 2009);
(iii) exocytosed and transferred ASYN serves as aggregation
seed for endogenous ASYN in the respective recipient cells
(Volpicelli-Daley et al. 2011). Both oligomeric ASYN, as
well as 4-hydroxy-2-nonenal (HNE) modiﬁed ASYN olig-
omers can serve as seeding-capable species (Danzer et al.
2009; Luk et al. 2009; Hansen and Li 2012; Bae et al.
2013). Similar to observations made with nitrated ASYN,
HNE-modiﬁed ASYN formes oligomers and is no longer
capable of polymerizing into amyloid-like ﬁbrils, but it can
trigger ﬁbrillation of unmodiﬁed ASYN (Bae et al. 2013).
According to the Braak hypothesis, Lewy body pathology in
idiopathic PD would spread along deﬁned paths from the
peripheral to the central nervous system (Braak et al. 1999,
2003, 2006; Braak and Braak 2000; Lee et al. 2011; Hansen
and Li 2012; Pan-Montojo et al. 2012). The role of tyrosine
nitration and methionine oxidation of ASYN has so far not
been investigated with respect to its inﬂuence on the
spreading of Lewy body pathology. However, recent
biochemical data suggest that HNE-modiﬁed ASYN could
indeed facilitate spreading of Lewy body pathology (Bae
et al. 2012). The role of other oxidative modiﬁcations or
post-translational modiﬁcations on ASYN’s seeding proper-
ties remains to be investigated. In these future studies, it will
be important to apply methodologies that allow the gener-
ation and analysis of site-speciﬁcly oxidized and/or post-
translationally modiﬁed ASYN. This will allow us to dissect
the relative contribution of oxidative modiﬁcations of each
residue and to explore potential cross-talk between the
different oxidized residues or different types of oxidative
modiﬁcations. If earlier observations are corroborated by
such more stringent approaches, oxidized ASYN could be a
promising target for pharmacological and immunological
intervention strategies.
Conclusions and Outlook
Evidence has been compiled here on the occurrence of
oxidative modiﬁcations of ASYN, the mechanisms involved
in this chemical modiﬁcation process, and the consequences
of such modiﬁcations on the properties and biological
function of the protein. The modiﬁcations affect various
toxic properties of ASYN and may have different conse-
quences, depending on the cellular context and metabolic
conditions. This important concept is clearly illustrated by
the following scenario: The C-terminus of ASYN is involved
in the binding of metals, such as Cu2+ or Fe2+, as well as in
the interaction of ASYN with other proteins such as tau.
Since several post-translational modiﬁcations, including
phosphorylation, nitration, and oxidation, occur within the
last 20 C-terminal amino acids of ASYN, it is plausible to
speculate that these post-translational modiﬁcations may act
independently or in concert as molecular switches for
regulating ASYN interactions with metals, small molecules
and proteins. Such effects would be highly dependent on the
speciﬁc brain region, cell type, and intracellular environment.
Furthermore, relatively universal oxidative modiﬁcations of
ASYN could result in cell/tissue-speciﬁc consequences in
different types of synucleinopathies and at different disease
stages.
Not all neuronal populations are equally susceptible to
neurodegenerative processes in synucleinopathies, and the
fact that DA cells are among the most vulnerable neurons,
strongly suggests an important role of oxidative reactions and
oxidatively modiﬁed forms of ASYN in their demise. We
have highlighted the special situation of dopaminergic
neurons. The oxidative environment, characteristic of these
neurons (because of their dopamine content) and nigral tissue
(susceptibility to neuroinﬂammation) in PD, provides a
conducive environment for oxidative modiﬁcations of
ASYN. Therefore, the potential gain of toxic function of
ASYN caused by its oxidative modiﬁcations is likely to be of
particular relevance for neurodegenerative processes target-
ing the nigrostriatal pathway. For instance, methionine
oxidation and tyrosine nitration lead to altered aggregation
processes. Some ASYN oligomeric species formed under
such conditions have been reported to be cytotoxic because
of their membrane permeabilizing/disruption properties. This
could lead to permeabilization of neurotransmitter vesicles
and/or mitochondrial damage, thus contributing to toxic
events that have long been associated with nigrostriatal
demise in PD.
It is important to emphasize that PD and other synuclein-
opathies are multifactorial diseases that share similarities but
are also characterized by signiﬁcant clinical and pathological
differences. In these diseases, region-speciﬁcity and other
pathological features would be unlikely to arise from a single
molecular initializing event. Rather, mechanistic interactions
involving ASYN, oxidative stress, proteostatic stress, and
other factors are supposable to take place in the affected
cells/tissues (Fig. 1). Speciﬁc combinations of toxic events
would ultimately lead to disease features unique to PD,
multiple system atrophy, or other synucleinopathies. Oxida-
tive modiﬁcations of ASYN should be seen more and more
within the context of such interactive pathogenetic mecha-
nisms.
In addition to tyrosine nitration and methionine oxidation,
several other post-translational modiﬁcations of ASYN, such
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as ubiquitination, glycation, SUMOylation, or phosphoryla-
tion, are subjects of intensive research efforts (Engelender
2008; Oueslati et al. 2010; Vicente Miranda and Outeiro
2010; Braithwaite et al. 2012). In the future, it will be
important to consider the cross-talk between these different
modiﬁcations and to determine how they regulate each other.
For instance, tyrosine nitration may affect phosphorylation of
tyrosines. As mentioned earlier, previous studies on the
impact of oxidative modiﬁcations on ASYN were often
hampered by the generation of mixtures of ASYN species
with different modiﬁcation patterns. Recent advances that
allow the synthesis of homogeneously and site-speciﬁcally
modiﬁed forms of ASYN will undoubtedly provide more
reﬁned insights into the role of oxidative modiﬁcations on
ASYN’s biology (Hejjaoui et al. 2011, 2012; Butterﬁeld
et al. 2012).
Not all post-translational modiﬁcations act necessarily as
gain of toxic function mechanisms. In fact, loss of normal
ASYN function might be sufﬁcient to contribute to neurode-
generation. For instance, as discussed above, it can be
hypothesized that normal ASYN plays a role as an antiox-
idant in the brain. An oxidation–reduction cycle involving
ASYN methionine sulfoxidation and methionine sulfoxide
reductase activity may protect brain cells when sufﬁcient
levels of soluble ASYN are present. Quite in contrast to
methionine oxidation, nitration of tyrosine residues seems to
be an irreversible ASYN modiﬁcation of potential toxic
relevance. Relatively high levels of •NO are a prerequisite for
sufﬁcient •NO2 radical generation and nitration reactions.
Such high levels of •NO only originate from the inducible
isoform of nitric oxide synthase-2 that is expressed in glial
cells upon inﬂammatory activation (Galea et al. 1992;
Hewett and Hewett 2012). Nitration of ASYN may therefore
only occur during more advanced stages of the degenerative
process and perhaps trigger a vicious cycle in which the
interaction between ASYN, oxidative stress, and other toxic
mechanisms leads to irreversible cell damage.
A ﬁnal consideration relates to the importance of translat-
ing knowledge on ASYN properties, including its oxidative
and nitrative modiﬁcations, into strategies to prevent its toxic
potential. One treatment strategy could be the use of NOS-2
selective inhibitors that are already in development for
diseases of the cardiovascular system. Brain NOS-2 inhibi-
tion could decrease the irreversible nitration of ASYN and
other proteins without interfering with normal redox regu-
latory processes mediated by basal •NO levels derived from
the constitutively expressed NOS-1 and NOS-3. Rodent
models using double expression of ASYN and NOS-2 are
already available and could be excellent tools for testing
potential therapeutics (Stone et al. 2012). Since intercellular
transfer of unmodiﬁed or modiﬁed ASYN is likely to play a
role in disease progression, immune therapy with speciﬁc
antibodies represents a promising approach. Indeed, beneﬁ-
cial effects of anti-ASYN antibodies have already been
reported in cell culture models (N€asstr€om et al. 2011b) and
in rodents (Masliah et al. 2005; Bae et al. 2012). A third
pharmacological intervention strategy could target speciﬁc
ROS sources. One important source of •O2
 are enzymes of
the NADPH oxidase family, such as NOX1 (Cheret et al.
2008). Inhibitors of this enzyme, capable of crossing the
blood–brain barrier, may be used either alone or in combi-
nation with NOS-2 inhibitors and could contribute to a
reduction of oxidative protein modiﬁcations associated with
PD and other neurodegenerative diseases. Future testing of
putative protective agents should take advantage of new
experimental models of ASYN pathophysiology and human
synucleinopathies (Fig. 9). These models include human
neural cells that could, for example, be generated from
Fig. 9 Burningquestions for future research.
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patient-derived induced pluripotent stem cells (Liu et al.
2012) or from engineered neural precursors (Lotharius et al.
2005; Scholz et al. 2011, 2013). Animal models in which
oxidative modiﬁcations of ASYN can be observed, as well as
rodents displaying progressive development of ASYN
pathology have been described in the literature (Luk et al.
2012a; McCormack et al. 2012).
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